Texas Permanent School Fund Raises Stock Position in Inogen, Inc. (NASDAQ:INGN)

Texas Permanent School Fund increased its stake in Inogen, Inc. (NASDAQ:INGNGet Rating) by 10.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,364 shares of the medical technology company’s stock after purchasing an additional 1,602 shares during the period. Texas Permanent School Fund owned 0.07% of Inogen worth $397,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Legal & General Group Plc boosted its stake in Inogen by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 57,104 shares of the medical technology company’s stock worth $1,380,000 after purchasing an additional 434 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in Inogen by 17.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 3,452 shares of the medical technology company’s stock valued at $83,000 after acquiring an additional 506 shares during the period. Captrust Financial Advisors lifted its stake in Inogen by 124.7% during the 1st quarter. Captrust Financial Advisors now owns 993 shares of the medical technology company’s stock valued at $32,000 after acquiring an additional 551 shares during the period. US Bancorp DE lifted its stake in Inogen by 273.0% during the 1st quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 647 shares during the period. Finally, American International Group Inc. lifted its stake in Inogen by 7.6% during the 2nd quarter. American International Group Inc. now owns 12,276 shares of the medical technology company’s stock valued at $297,000 after acquiring an additional 869 shares during the period. 95.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on the stock. Needham & Company LLC decreased their price objective on shares of Inogen from $45.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday, November 2nd. JPMorgan Chase & Co. cut their target price on shares of Inogen from $32.00 to $22.00 and set a “neutral” rating for the company in a report on Thursday, November 3rd. Finally, StockNews.com began coverage on shares of Inogen in a report on Wednesday, October 12th. They set a “hold” rating for the company.

Inogen Price Performance

NASDAQ INGN opened at $23.28 on Monday. The firm’s 50-day moving average is $21.45 and its two-hundred day moving average is $24.36. Inogen, Inc. has a 12 month low of $19.08 and a 12 month high of $36.30. The stock has a market capitalization of $533.60 million, a P/E ratio of -10.58 and a beta of 0.93.

Inogen (NASDAQ:INGNGet Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The medical technology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.23. The business had revenue of $105.39 million for the quarter, compared to analysts’ expectations of $97.57 million. Inogen had a negative net margin of 13.69% and a negative return on equity of 11.02%. As a group, analysts anticipate that Inogen, Inc. will post -1.88 EPS for the current year.

Inogen Company Profile

(Get Rating)

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc. (NASDAQ:INGNGet Rating).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.